Clinical use of thymidine as a rescue agent from methotrexate toxicity

Jean L. Grem, Susan A. King, J. Mel Sorensen, Michaele C. Christian

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Thymidine has been available for clinical research as a rescue agent since 1978 under sponsorship of the Division of Cancer Treatment, National Cancer Institute. Renal insufficiency following administration of high dose methotrexate results in prolonged exposure to toxic concentrations of drug. Thymidine has been used in conjunction with leucovorin and alkaline hydration to protect patients with acute renal dysfunction from life-threatening methotrexate toxicity. The outcome of eight cases in which thymidine was released under the special exception mechanism to treat patients who developed acute renal failure following methotrexate are reported. The clinical trials using thymidine in combination with methotrexate in patients with normal renal function are also reviewed.

Original languageEnglish (US)
Pages (from-to)281-290
Number of pages10
JournalInvestigational New Drugs
Issue number3
StatePublished - Aug 1991
Externally publishedYes


  • high-dose methotrexate
  • thymidine rescue

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical use of thymidine as a rescue agent from methotrexate toxicity'. Together they form a unique fingerprint.

Cite this